Petros Pharmaceuticals, Inc. - Common Stock

Share · US71678J2096 · PTPI (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Petros Pharmaceuticals, Inc. - Common Stock

No Price

28.04.2026 19:48

Current Prices from Petros Pharmaceuticals, Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	PTPI	USD	28.04.2026 19:48	0,007 USD	0,0002 USD +2,86 %

Share Float & Liquidity

Free Float 99,80 %

Shares Float 31,1 M

Shares Outstanding 31,16 M

Company Profile for Petros Pharmaceuticals, Inc. - Common Stock Share

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.